Tenax Therapeutics (TENX) Stock Price, Quote & News

Company Profile

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was for...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 855 2100

Website: www.tenaxthera.com

Address:

101 Glen Lennox Drive, Suite 300, Chapel Hill, United States

MihalisB86 Sep. 4 at 8:31 AM

$TENX They have given the public ample time to load under $2 for weeks! ADAR1 Capital Management bought over $5 million shares around $1.80. I guarantee you they will want this over $5 by years end! Long and strong will prosper!

0 · Reply

Robert345 Sep. 4 at 4:32 AM

$TENX Last post I just made was Part 1 This is Part 2 I'M LOADING UP !!!!

1 · Reply

Robert345 Sep. 4 at 4:29 AM

$TENX I'm assuming the price will spike up after his talk when the bell rings at 9:30am !!!!! If he's a GREAT speaker, everyone will want to BUY BUY BUY 😁😁😁!!!!!!!!!

0 · Reply

modrica3 Sep. 3 at 11:18 PM

$TENX wasnt this $18 in july ? now 1.80 how da hek it dropped 90% ?

2 · Reply

MihalisB86 Sep. 3 at 11:09 PM

$TENX A good PR with news about the conference makes this fly

0 · Reply

dorpsgen Sep. 3 at 10:52 PM

$TENX IMO, LEVEL's failure was mainly a population/power problem. The responder population is clear enough to design LEVEL-2 much stronger.

1 · Reply

dorpsgen Sep. 3 at 10:40 PM

$TENX after seeing the full public LEVEL data, ADAR1 seems willing to use a very large amount of capital on the idea that the market greatly underestimates the value of the enriched TNX-103/FDA route.

1 · Reply

modrica3 Sep. 3 at 10:11 PM

$TENX that drop at the end today was unnecceseary really

0 · Reply

MihalisB86 Sep. 3 at 9:24 PM

$TENX Better days are ahead, we have to be strong and patient!

1 · Reply

Ilygod Sep. 3 at 8:42 PM

$TENX Here's a thought. CEO, CFO and Directors are so underwater on their options. Who knows but they may be the ones buying here and keeping the prices down.

0 · Reply

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

2026-08-31T11:10:34.000Z - 3 days ago

Guggenheim downgrades Tenax Therapeutics on clinical, regulatory uncertainty

2026-08-31T10:15:27.000Z - 3 days ago

Tenax Therapeutics downgraded to Neutral from Buy at Guggenheim

2026-08-30T19:35:10.000Z - 4 days ago

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

Aug 29, 2026, 8:21 AM EDT - 5 days ago

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Aug 16, 2026, 5:38 PM EDT - 18 days ago

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Aug 13, 2026, 12:47 PM EDT - 21 days ago

TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

2026-08-11T15:40:20.000Z - 23 days ago

Tenax Therapeutics downgraded to Neutral from Buy at Chardan

2026-08-11T11:00:43.000Z - 23 days ago

Tenax Therapeutics price target lowered to $4 from $35 at Canaccord

2026-08-11T10:51:10.000Z - 23 days ago

Tenax Therapeutics price target lowered to $4 from $40 at Guggenheim

2026-08-11T10:15:39.000Z - 23 days ago

Tenax Therapeutics price target lowered to $4 from $26 at Leerink

2026-08-10T20:25:43.000Z - 24 days ago

Tenax Therapeutics downgraded to In Line from Outperform at Evercore ISI

2026-08-10T16:55:12.000Z - 24 days ago

Tenax Therapeutics downgraded to Market Perform from Outperform at William Blair

2026-08-10T14:30:10.000Z - 24 days ago

Tenax Therapeutics price target lowered to $5 from $30 at Roth Capital

Aug 10, 2026, 8:00 AM EDT - 24 days ago

Tenax Therapeutics Transcript: Study result

Aug 10, 2026, 8:00 AM EDT - 24 days ago

Tenax Therapeutics Slides: Study result

Aug 10, 2026, 8:00 AM EDT - 24 days ago

Tenax Therapeutics Press release: Study result

2026-08-10T11:35:31.000Z - 24 days ago

Tenax Therapeutics reports LEVEL trial did not meet primary endpoint

Aug 10, 2026, 7:12 AM EDT - 24 days ago

Tenax Therapeutics' heart drug misses main goal in study, shares plunge

Aug 10, 2026, 7:00 AM EDT - 24 days ago

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Jul 31, 2026, 7:30 AM EDT - 4 weeks ago

Tenax Therapeutics Earnings release: Q2 2026

Jul 31, 2026, 7:30 AM EDT - 4 weeks ago

Tenax Therapeutics Quarterly report: Q2 2026

2026-07-31T11:06:52.000Z - 4 weeks ago

Tenax Therapeutics reports Q2 EPS (35c), consensus (36c)

Jul 31, 2026, 7:00 AM EDT - 4 weeks ago

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2026-07-28T11:15:43.000Z - 5 weeks ago

Tenax Therapeutics initiated with a Buy at Canaccord

2026-07-28T10:25:52.000Z - 5 weeks ago

Tenax Therapeutics initiated with a Buy at Canaccord

2026-07-22T12:11:24.000Z - 6 weeks ago

Tenax Therapeutics initiated with an Outperform at Evercore ISI

Jul 2, 2026, 4:05 PM EDT - 2 months ago

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2026, 7:00 AM EDT - 2 months ago

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

2026-06-22T10:50:38.000Z - 2 months ago

Tenax Therapeutics price target raised to $40 from $34 at Guggenheim

May 12, 2026, 8:00 AM EDT - 3 months ago

Tenax Therapeutics Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Tenax Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 4, 2026, 7:00 AM EDT - 4 months ago

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Tenax Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Tenax Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Tenax Therapeutics Registration statement: Registration filing

Mar 10, 2026, 2:20 PM EDT - 5 months ago

Tenax Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Tenax Therapeutics Annual report: Q4 2025

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Tenax Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Tenax Therapeutics Slides: Corporate presentation

Mar 3, 2026, 7:00 AM EST - 6 months ago

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Feb 11, 2026, 12:30 PM EST - 6 months ago

Tenax Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 7 months ago

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Dec 17, 2025, 9:16 AM EST - 8 months ago

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Dec 4, 2025, 11:30 AM EST - 9 months ago

Tenax Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 4:15 PM EST - 9 months ago

Tenax Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:00 AM EST - 9 months ago

Tenax Therapeutics to Participate in Upcoming Investor Conferences

Nov 13, 2025, 4:30 PM EST - 9 months ago

Tenax Therapeutics Transcript: KOL Event

Nov 12, 2025, 4:05 PM EST - 9 months ago

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:00 PM EST - 9 months ago

Tenax Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

Tenax Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 9 months ago

Tenax Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:00 AM EST - 10 months ago

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Nov 3, 2025, 7:00 AM EST - 10 months ago

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Sep 16, 2025, 7:00 AM EDT - 11 months ago

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Sep 4, 2025, 10:20 AM EDT - 12 months ago

Tenax Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Tenax Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Tenax Therapeutics Earnings release: Q2 2025

Jun 26, 2025, 7:00 AM EDT - 1 year ago

Tenax Therapeutics Slides: Corporate Presentation

May 14, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 12:30 PM EDT - 1 year ago

Tenax Therapeutics Earnings release: Q1 2025

May 14, 2025, 12:30 PM EDT - 1 year ago

Tenax Therapeutics Quarterly report: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Registration statement: Registration Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 3:45 PM EDT - 1 year ago

Tenax Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 7:00 AM EDT - 1 year ago

Tenax Therapeutics Slides: Corporate Presentation

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Tenax Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 8:47 AM EST - 1 year ago

Tenax Therapeutics Announces $25 Million Private Placement

Mar 5, 2025, 8:42 AM EST - 1 year ago

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Mar 5, 2025, 7:00 AM EST - 1 year ago

Tenax Therapeutics Slides: Corporate Presentation

Mar 3, 2025, 8:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Feb 5, 2025, 3:00 PM EST - 1 year ago

Tenax Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 9:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

Tenax Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Tenax Therapeutics Earnings release: Q3 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Sep 27, 2024, 8:00 AM EDT - 1 year ago

Tenax Therapeutics Proxy statement: Proxy Filing

Aug 30, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Tenax Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Tenax Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 7:13 AM EDT - 2 years ago

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

May 24, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Proxy statement: Proxy Filing

May 14, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 14, 2024, 7:00 AM EDT - 2 years ago

Tenax Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Tenax Therapeutics Earnings release: Q1 2024

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Proxy statement: Proxy Filing

Apr 9, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Feb 29, 2024, 9:00 AM EST - 2 years ago

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Feb 20, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Feb 8, 2024, 8:16 AM EST - 2 years ago

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Feb 7, 2024, 8:01 PM EST - 2 years ago

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 6, 2024, 10:01 AM EST - 2 years ago

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Feb 6, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 2, 2024, 7:00 AM EST - 2 years ago

Tenax Therapeutics Registration statement: Registration Filing

Feb 1, 2024, 7:00 AM EST - 2 years ago

Tenax Therapeutics Registration statement: Registration Filing

Dec 29, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Reverse Stock Split

Dec 1, 2023, 7:00 AM EST - 2 years ago

Tenax Therapeutics Registration statement: Registration Filing

Nov 17, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

MihalisB86 Sep. 4 at 8:31 AM

0 · Reply

Robert345 Sep. 4 at 4:32 AM

$TENX Last post I just made was Part 1 This is Part 2 I'M LOADING UP !!!!

1 · Reply

Robert345 Sep. 4 at 4:29 AM

$TENX I'm assuming the price will spike up after his talk when the bell rings at 9:30am !!!!! If he's a GREAT speaker, everyone will want to BUY BUY BUY 😁😁😁!!!!!!!!!

0 · Reply

modrica3 Sep. 3 at 11:18 PM

$TENX wasnt this $18 in july ? now 1.80 how da hek it dropped 90% ?

2 · Reply

MihalisB86 Sep. 3 at 11:09 PM

$TENX A good PR with news about the conference makes this fly

0 · Reply

dorpsgen Sep. 3 at 10:52 PM

$TENX IMO, LEVEL's failure was mainly a population/power problem. The responder population is clear enough to design LEVEL-2 much stronger.

1 · Reply

dorpsgen Sep. 3 at 10:40 PM

1 · Reply

modrica3 Sep. 3 at 10:11 PM

$TENX that drop at the end today was unnecceseary really

0 · Reply

MihalisB86 Sep. 3 at 9:24 PM

$TENX Better days are ahead, we have to be strong and patient!

1 · Reply

Ilygod Sep. 3 at 8:42 PM

$TENX Here's a thought. CEO, CFO and Directors are so underwater on their options. Who knows but they may be the ones buying here and keeping the prices down.

0 · Reply

Greenplease01 Sep. 3 at 8:30 PM

In at 1.78 $TENX

0 · Reply

anderbear Sep. 3 at 8:10 PM

$TENX Who the fuck do you think you are? Two dollars is a good buy. If you want to get rich overnight, go to a casino and bet on red. Idiot.

0 · Reply

roaringpusss Sep. 3 at 7:53 PM

$TENX quick reload on the dip

0 · Reply

mikethemage Sep. 3 at 7:53 PM

$TENX shut the fuck up, I told you this shit will be 1.80 by eod. You told me good buy at $2 liar

2 · Reply

MihalisB86 Sep. 3 at 7:51 PM

$TENX

0 · Reply

TribalSublime Sep. 3 at 7:51 PM

$TENX What a day...both of my positions were in solid green early on and got destroyed...$CRDO

0 · Reply

User123321 Sep. 3 at 7:41 PM

$TENX Gap filled and then some but also a really weak day for biotech.

0 · Reply

jtsxlr Sep. 3 at 7:38 PM

$TENX Well This is a bust

0 · Reply

Trendsetta69 Sep. 3 at 7:23 PM

$TENX gap filled

0 · Reply

Cryptotherapist Sep. 3 at 7:13 PM

$TENX glad their average higher than mine. Annoying

0 · Reply

MrMilano1990 Sep. 3 at 7:12 PM

$TENX Patience, don't worry over a trading day. Let daily traders do what they like and fortune seekers for squezzees hope for millions in profit on a day. Know what you are holdig and let this grow on it's own. I'm holding this and I'm dosen't bother if we are down today. Don't sell on loss if you belive in the stock. Hold and keep buying if you have opportunity to do so 🙏 Life isn't a sprint it's a Marathon 👏

1 · Reply

1956chill Sep. 3 at 7:10 PM

$TENX shaking off week hands... do your own DD

0 · Reply

Market Cap	69.23M
Revenue (ttm)	0.00
Net Income (ttm)	-52.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	14,085,199
Avg Vol	5,824,098
Day's Range	N/A - N/A
Shares Out	37.42M
Stochastic %K	12%
Beta	0.83
Analysts	Strong Sell
Price Target	$13.38